8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)   October 25, 2016

HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts	1-14041	04-2882273
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

400 Wood Road, Braintree MA	02184
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code  781-848-7100

(Former name or former address, if changed since last report.)

	Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02(d) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Election of Catherine M. Burzik to the Board of Directors

On October 25, 2016 the Haemonetics Corporation Board of Directors elected Catherine M. Burzik as a Class I Director for a term which expires at the 2018 Annual Meeting of Shareholders. Ms. Burzik was also appointed to the Audit Committee.

As of the date of her election, Ms. Burzik is entitled to receive compensation and participate in the plans applicable to all directors, as more particularly described on page 46 of the Haemonetics’ proxy statement filed June 10, 2016, under the heading “Directors’ Compensation”.

In connection with her election, Ms. Burzik received an initial grant of Restricted Stock Units valued at $170,000.00. The Restricted Stock Units vest on the first anniversary of grant and are issued under the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan. The terms and conditions of this equity award are consistent with the Company’s equity award agreements filed by the Company as exhibits to the 10-K filed with the Securities and Exchange Commission for the fiscal year ended March 28, 2015.

The selection of Ms. Burzik was not pursuant to any arrangement or understanding with respect to any other person. In addition, there are no actual or proposed transactions between Ms. Burzik or any of her related persons and Haemonetics which would require disclosure under Item 404(a) of Regulation S-K (17 CFR 229.404(a)).

Section 9 - Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits
(d)	Exhibits:
Exhibit Number		Exhibit Description
99.1		Press Release Regarding Election of Catherine M. Burzik to Haemonetics Corporation's Board of Directors

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HAEMONETICS CORPORATION
	(Registrant)
Date: October 27, 2016	By	/s/ Sandra Jesse
		Sandra Jesse, Executive Vice President
		and Chief Legal Officer

EX-99.1

News Release

FOR RELEASE:		Investor Contact
Date	October 27, 2016	Gerry Gould, VP-Investor Relations
Time	4:00pm Eastern	(781) 356-9402
		gerry.gould@haemonetics.com
		Media Contact
		Sandra Jesse, Executive VP
		(781) 356-9253
		sandra.jesse@haemonetics.com

Catherine M. Burzik Joins Haemonetics Board of Directors

Braintree, MA, October 27, 2016 – Haemonetics Corporation (NYSE:HAE) announced the election of Catherine M. Burzik, a highly respected and accomplished senior executive in the healthcare industry, to its Board of Directors. Ms. Burzik successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses.

Richard J. Meelia, Chairman of Haemonetics’ Board of Directors commented, “Cathy Burzik brings extensive experience as a superb operator and a highly effective value creator in the healthcare industry. She has demonstrated the ability to apply innovative and strategic direction, leading to the creation of significant shareholder value. We welcome her and look forward to her contribution to our Company’s success.”

"Haemonetics’ products and services address the key focal points of the health care industry – providing the best possible clinical outcomes for clinicians and their patients, while managing cost structures.” said Ms. Burzik. "I look forward to joining the Board of Directors and serving the Company's shareholders."

Until the sale of the company in 2012, she served as President, Chief Executive Officer and Director of Kinetic Concepts, Inc., a medical device company specializing in wound care and regenerative medicine. Her prior positions include President of Applied Biosystems Group, a pioneer DNA sequencing company, President of Ortho Clinical Diagnostics and Critikon divisions of Johnson & Johnson and senior positions with MITRE Corporation and Eastman Kodak Company.

Ms. Burzik currently serves on the Boards of Directors of Becton Dickinson & Company (NYSE:BDX) and Xenex Disinfection Services LLC, , and is non-executive chairman of the Board of Directors of StemBioSys, Inc. She previously served on the Boards of Directors of Allscripts, Bausch and Lomb, Cordis Corporation, the San Antonio Branch of the Dallas

Federal Reserve Board, Innovative Trauma Care Ltd., Kinetic Concepts, Inc., and VitaPath Genetics, Inc.

Ms. Burzik is currently a general partner with Targeted Technology Fund II, a fund within Targeted Technologies LLC, an early stage venture capital firm focused on medical device, life sciences and biotech investments. She is also Founder and CEO of the Catherine and Francis Burzik Foundation and has served on a number of non-profit boards. Her education includes a Bachelor’s in Mathematics from Canisius College and a Master’s in Mathematics from the University of Buffalo.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit http://www.haemonetics.com.